Skip to main content

Market Overview

Bill Gates Says 6 COVID-19 Vaccines Likely To Get Regulatory Approval By Q1

Share:
Bill Gates Says 6 COVID-19 Vaccines Likely To Get Regulatory Approval By Q1

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates said that nearly half a dozen vaccines from different manufacturers could be available by the spring of 2021, CNBC reported Tuesday.

What Happened: “I expect that we’ll have about six vaccines approved by the first quarter,” the billionaire philanthropist said, speaking through videoconferencing at Singapore’s fintech Festival, CNBC reported.

Apart from Pfizer Inc (NYSE: PFE) and BioNTech’s SE (NASDAQ: BNTX) vaccine — which has gained approval in some geographies, candidates from Moderna Inc (NASDAQ: MRNA), AstraZeneca Plc (NASDAQ: AZN), Johnson & Johnson (NYSE: JNJ) and Novavax, Inc (NASDAQ: NVAX) could get regulatory approval in the coming months, according to Gates.

Why It Matters: Gates did not name the sixth vaccine and praised the regulators for “doing a great job,” as per CNBC.

Previously, Gates had said that he was “optimistic” that multiple vaccines would “prove very efficacious and safe” by February.

Pfizer’s COVID-19 vaccine could get emergency approval as early as Friday, according to a United States Food and Drugs Administration Advisor.

The company received emergency approval for its vaccine in the United Kingdom this month.

Pfizer has also applied for approval on an emergency basis in India, which has the second-highest number of coronavirus cases after the U.S.

Price Action: Microsoft shares closed unchanged at $214.29 on Monday and fell 0.28% in the after-hours session.

Related Link: Pfizer Tells US It Can't Provide Substantial Extra Doses Before June As Other Countries Have Already Secured Supply: WaPo

Photo courtesy of Kuhlmann via Wikimedia

 

Related Articles (AZN + BNTX)

View Comments and Join the Discussion!

Posted-In: Bill Gates CNBC Covid-19 VaccinesBiotech News Media General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com